CMN 572 ACTUAL 2026 EXAM QUESTIONS AND
ANSWERS GRADED A+
✔✔Molluscum contagiosum: - ✔✔papules with central dimple, caused by a pox virus;
rarely involves mucosal surfaces
✔✔CDC-Recommended Regimens For External Genital Warts: Patient-Applied &
Provider Applied - ✔✔Patient Applied:
Podofilox 0.5% solution or gel (Condylox™)
Patients should apply solution with cotton swab or gel with a finger to visible warts twice
a day for 3 days, followed by 4 days of no therapy.
Cycle may be repeated as needed up to 4 cycles.
OR
Imiquimod 3.75 or 5% cream (Aldara™)
Patients should apply cream once daily at bedtime, 3 times a week for up to 16 weeks.
Treatment area should be washed with soap and water 6-10 hours after application.
OR
Sinecatechins 15% ointment
Patients should apply the ointment 3 times daily for up to 16 weeks
Medication should not be washed off and sexual contact should be avoided while
medication is on skin
Provider Applied:
Cryotherapy with liquid nitrogen or cryoprobe
Repeat applications every 1-2 weeks, OR
Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%-90%
Surgical removal--tangential scissor excision, tangential shave excision, curettage, or
electrosurgery
✔✔CDC-Recommended Regimens for Vaginal & Anal Warts - ✔✔Cryotherapy with
liquid nitrogen
The use of a cryoprobe in the vagina is not recommended because of risk for vaginal
perforation and fistula formation.
OR
TCA or BCA 80%-90% applied to warts
Apply small amount only to warts and allow to dry (white "frosting" develops).
Treatment may be repeated weekly if needed.
✔✔CDC-Recommended Regimens for Urethral Meatus & Oral Warts - ✔✔Cryotherapy
with liquid nitrogen
OR
Surgical removal
,✔✔Management of Genital Warts in Pregnancy - ✔✔Genital warts can proliferate and
become more friable during pregnancy.
Cytotoxic agents (podophyllin, podofilox, imiquimod, sinecateshins) should not be used.
Removal may be considered but resolution is poor or incomplete during pregnancy
Prevention value of cesarean delivery is unknown, thus C-section should not be
performed solely to prevent transmission to neonate
✔✔Management of Genital Warts in Immunodeficient Patients - ✔✔More frequent
occurance, resistance to treatment, atypical lesions r/t immunodeficiency
Treatment unlikely to be effective due to high recurrence rate; therefore, treat only if the
patient is symptomatic.
✔✔re-occurrence of genital warts protocol: - ✔✔Up to 2/3 of patients will experience
recurrences of warts within 6-12 weeks of therapy; after 6 months most patients have
clearance.
If persistent after 3 months, or if there is poor response to treatment or hyperpigmented
lesions, consider biopsy to exclude a premalignant or neoplastic condition, especially in
an immunocompromised person.
Treatment modality should be changed if patient has not improved substantially after 3
provider-administered treatments or if warts do not completely clear after 6 treatments.
✔✔Pap Test Screening in Immunodeficient Patients - ✔✔Immunodeficiency appears to
accelerate intraepithelial neoplasia and invasive cancer
Provide cervical Pap test screening every 6 months for 1 year, then annually for all HIV-
infected women with or without genital warts
✔✔Genital Wart Follow-Up - ✔✔Counsel patients to:
Watch for recurrences
Get regular Pap screening at intervals as recommended for women WITHOUT genital
warts
After visible warts have cleared, follow-up evaluation not mandatory, but provides
opportunity to:
Monitor or treat complications of therapy
Document the absence of warts
Reinforce patient education and counseling messages
Offer patients concerned about recurrences a follow-up evaluation 3 months after
treatment.
, Primary goal is removal of symptomatic warts.
No evidence that presence of genital warts or their treatment is associated with
development of cervical cancer
✔✔Partner Management & Risk reduction of HPV - ✔✔Abstinence and long-term
mutual monogamy with an uninfected partner are the most effective options to prevent
transmission.
HPV infections can occur in male and female genital areas that are not covered by a
latex condom, as well as in areas that are covered
Likelihood of transmission and duration of infectivity with or without treatment are
unknown.
Sex partner examination is not necessary
✔✔What is Pelvic Inflammatory Disease (PID)? - ✔✔ascending spread of
microorganisms from the vagina or cervix to the endometrium, fallopian tubes, ovaries,
and contiguous structures.
✔✔risk factors associated with PID - ✔✔Adolescence
Gonorrhea or chlamydia, or a history of
Male partners with gonorrhea or chlamydia
Multiple partners
Current douching
Insertion of IUD
Bacterial vaginosis
Oral contraceptive use (in some cases)
Demographics (socioeconomic status)
✔✔most common pathogens causing PID: - ✔✔Neisseria gonorrhea and chlamydia
trachomatis
✔✔Minimum Criteria in the Diagnosis of PID - ✔✔Uterine tenderness, or
Adnexal tenderness, or
Cervical motion tenderness
✔✔Additional Diagnostic Criteria to Increase Specificity of PID Diagnosis -
✔✔Temperature >38.3°C (101°F)
Abnormal cervical or vaginal mucopurulent discharge
Presence of abundant numbers of WBCs on saline microscopy of vaginal secretions
Elevated erythrocyte sedimentation rate (ESR)
Elevated C-reactive protein (CRP)
ANSWERS GRADED A+
✔✔Molluscum contagiosum: - ✔✔papules with central dimple, caused by a pox virus;
rarely involves mucosal surfaces
✔✔CDC-Recommended Regimens For External Genital Warts: Patient-Applied &
Provider Applied - ✔✔Patient Applied:
Podofilox 0.5% solution or gel (Condylox™)
Patients should apply solution with cotton swab or gel with a finger to visible warts twice
a day for 3 days, followed by 4 days of no therapy.
Cycle may be repeated as needed up to 4 cycles.
OR
Imiquimod 3.75 or 5% cream (Aldara™)
Patients should apply cream once daily at bedtime, 3 times a week for up to 16 weeks.
Treatment area should be washed with soap and water 6-10 hours after application.
OR
Sinecatechins 15% ointment
Patients should apply the ointment 3 times daily for up to 16 weeks
Medication should not be washed off and sexual contact should be avoided while
medication is on skin
Provider Applied:
Cryotherapy with liquid nitrogen or cryoprobe
Repeat applications every 1-2 weeks, OR
Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%-90%
Surgical removal--tangential scissor excision, tangential shave excision, curettage, or
electrosurgery
✔✔CDC-Recommended Regimens for Vaginal & Anal Warts - ✔✔Cryotherapy with
liquid nitrogen
The use of a cryoprobe in the vagina is not recommended because of risk for vaginal
perforation and fistula formation.
OR
TCA or BCA 80%-90% applied to warts
Apply small amount only to warts and allow to dry (white "frosting" develops).
Treatment may be repeated weekly if needed.
✔✔CDC-Recommended Regimens for Urethral Meatus & Oral Warts - ✔✔Cryotherapy
with liquid nitrogen
OR
Surgical removal
,✔✔Management of Genital Warts in Pregnancy - ✔✔Genital warts can proliferate and
become more friable during pregnancy.
Cytotoxic agents (podophyllin, podofilox, imiquimod, sinecateshins) should not be used.
Removal may be considered but resolution is poor or incomplete during pregnancy
Prevention value of cesarean delivery is unknown, thus C-section should not be
performed solely to prevent transmission to neonate
✔✔Management of Genital Warts in Immunodeficient Patients - ✔✔More frequent
occurance, resistance to treatment, atypical lesions r/t immunodeficiency
Treatment unlikely to be effective due to high recurrence rate; therefore, treat only if the
patient is symptomatic.
✔✔re-occurrence of genital warts protocol: - ✔✔Up to 2/3 of patients will experience
recurrences of warts within 6-12 weeks of therapy; after 6 months most patients have
clearance.
If persistent after 3 months, or if there is poor response to treatment or hyperpigmented
lesions, consider biopsy to exclude a premalignant or neoplastic condition, especially in
an immunocompromised person.
Treatment modality should be changed if patient has not improved substantially after 3
provider-administered treatments or if warts do not completely clear after 6 treatments.
✔✔Pap Test Screening in Immunodeficient Patients - ✔✔Immunodeficiency appears to
accelerate intraepithelial neoplasia and invasive cancer
Provide cervical Pap test screening every 6 months for 1 year, then annually for all HIV-
infected women with or without genital warts
✔✔Genital Wart Follow-Up - ✔✔Counsel patients to:
Watch for recurrences
Get regular Pap screening at intervals as recommended for women WITHOUT genital
warts
After visible warts have cleared, follow-up evaluation not mandatory, but provides
opportunity to:
Monitor or treat complications of therapy
Document the absence of warts
Reinforce patient education and counseling messages
Offer patients concerned about recurrences a follow-up evaluation 3 months after
treatment.
, Primary goal is removal of symptomatic warts.
No evidence that presence of genital warts or their treatment is associated with
development of cervical cancer
✔✔Partner Management & Risk reduction of HPV - ✔✔Abstinence and long-term
mutual monogamy with an uninfected partner are the most effective options to prevent
transmission.
HPV infections can occur in male and female genital areas that are not covered by a
latex condom, as well as in areas that are covered
Likelihood of transmission and duration of infectivity with or without treatment are
unknown.
Sex partner examination is not necessary
✔✔What is Pelvic Inflammatory Disease (PID)? - ✔✔ascending spread of
microorganisms from the vagina or cervix to the endometrium, fallopian tubes, ovaries,
and contiguous structures.
✔✔risk factors associated with PID - ✔✔Adolescence
Gonorrhea or chlamydia, or a history of
Male partners with gonorrhea or chlamydia
Multiple partners
Current douching
Insertion of IUD
Bacterial vaginosis
Oral contraceptive use (in some cases)
Demographics (socioeconomic status)
✔✔most common pathogens causing PID: - ✔✔Neisseria gonorrhea and chlamydia
trachomatis
✔✔Minimum Criteria in the Diagnosis of PID - ✔✔Uterine tenderness, or
Adnexal tenderness, or
Cervical motion tenderness
✔✔Additional Diagnostic Criteria to Increase Specificity of PID Diagnosis -
✔✔Temperature >38.3°C (101°F)
Abnormal cervical or vaginal mucopurulent discharge
Presence of abundant numbers of WBCs on saline microscopy of vaginal secretions
Elevated erythrocyte sedimentation rate (ESR)
Elevated C-reactive protein (CRP)
